Tag Archives: safety

Arrhythmic risk: regression, single cell biophysics, or big tissue simulations?

On the 15th March I presented at an FDA public Advisory Committee hearing on the proposals of the CiPA initative. CiPA aims to replace the current testing for increased drug-induced Torsade de Pointes (TdP) arrhythmic risk, which is a human … Continue reading

Posted in Action Potential Models, Drug action, Future developments, Model Development, Safety Pharmacology, Tissue Simulations | Tagged , , , , , , , | 1 Comment